Authors
Latest:
Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin LymphomaMatthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.
Latest:
Key Takeaways and Closing Thoughts on ADCsExperts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.
Latest:
Dr Goetz on the Early Pharmacokinetic Data With Neoadjuvant (Z)-endoxifen in ER+/HER2– Breast CancerMatthew P. Goetz, MD, discusses pharmacokinetic data for neoadjuvant (Z)-endoxifen in estrogen receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLCMatthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic CancerAn integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Latest:
Dr. Kulke on Emerging Cabozantinib Data for NETsMatthew H. Kulke, MD, Dana-Farber Cancer Institute, discusses the emerging data seen with cabozantinib (Cabometyx) for patients with neuroendocrine tumors (NETs).
Latest:
Neuroendocrine Tumors: Options for Initial TherapyMatthew H. Kulke, MD, provides a broad overview of initial therapy options available for patients with neuroendocrine tumors.
Latest:
Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid TumorsMatthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.
Latest:
Dr. Matthew Katz on Borderline Resectable Pancreatic CancerMatthew H.G. Katz, MD, from the MD Anderson Cancer Center, discusses borderline resectable pancreatic ductal adenocarcinoma, a newer stage of pancreatic cancer introduced by the NCCN in 2003.
Latest:
Dr. Katz on Neoadjuvant Chemotherapy in Pancreatic CancerMatthew H.G. Katz, MD, FACS, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.
Latest:
Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast CancerMatthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.
Latest:
Dr Matasar on the Design of the OLYMPIA-3 Trial in DLBCLMatthew Matasar, MD, discusses the design of the phase 3 OLYMPIA-3 trial of odronextamab plus CHOP in treatment-naive intermediate- or high-risk DLBCL.
Latest:
Dr. Kulke on Unanswered Questions Surrounding the Treatment of NETsMatthew Kulke, MD, comments on some unanswered questions surrounding the treatment of neuroendocrine tumors (NETs).
Latest:
Dr. Ladra on the Treatment of Pediatric EsthesioneuroblastomaMatthew Ladra, MD, director, Pediatric Radiation Oncology, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, discusses the treatment of esthesioneuroblastoma in children.
Latest:
Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCLA panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
Latest:
As Practice Grows, Competitors LoomEstablished just nine years ago via the merger of three specialty practices and 14 physicians, Dayton Physicians Network, an independent, Ohio-based oncology group practice, has experienced rapid growth, fueled in part by increased Medicaid enrollment and profits from their oral drug dispensing program.
Latest:
Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast CancerMatthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.
Latest:
Dr. Schlumbrecht on Treatment in Uterine LeiomyosarcomaMatthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.
Latest:
Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial CancerMatthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.
Latest:
Dr. Cooperberg on Ongoing Trials in Early Prostate CancerMatthew R. Cooperberg, MD, MPH, an associate professor of urology, epidemiology, and biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (USCF), discusses ongoing trials in early prostate cancer.
Latest:
Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Risk in the Phase 3 ARASENS StudyExpert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Zibelman on Managing Immune-Related Adverse EventsMatthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).
Latest:
Dr. Davids on the Potential Utility of Frontline Ibrutinib/Umbralisib in CLL and MCLMatthew S. Davids, MD, MMSc, discusses the potential utility of moving the combination of ibrutinib and umbralisib into the frontline setting of chronic lymphocytic leukemia and mantle cell lymphoma.
Latest:
Clinical Pearls and Impacts to Practice from EHA 2024The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.
